Payment overview · 2025
General Payments
$414.33
21 reported records · 6 companies
Healthcare provider profile · identity verified
Steven Ching, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HEMET, CA · NPI 1770016081
Verified facts
What the public records show
CMS Open Payments records show Steven Ching, M.D. received $414.33 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.03 | 38.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $106.06 | 25.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.93 | 15.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.82 | 10.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.58 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.91 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $414.33 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.30 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.93 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.32 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.12 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.94 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1192 | 385 |
| Amlodipine Besylate | Amlodipine Besylate | 675 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 188 |
| Losartan Potassium | Losartan Potassium | 561 | 177 |
| Lisinopril | Lisinopril | 542 | 179 |
| Metformin Hcl | Metformin Hcl | 431 | 145 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 410 | 83 |
| Gabapentin | Gabapentin | 387 | 144 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 374 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 119 |
| Omeprazole | Omeprazole | 320 | 114 |
| Simvastatin | Simvastatin | 256 | 76 |
| Tramadol Hcl | Tramadol Hcl | 255 | 67 |
| Trazodone Hcl | Trazodone Hcl | 247 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 235 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 80 |
| Furosemide | Furosemide | 227 | 86 |
| Famotidine | Famotidine | 220 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 76 |
| Eliquis | Apixaban | 202 | 58 |
| Carvedilol | Carvedilol | 168 | 53 |
| Glipizide | Glipizide | 166 | 57 |
| Potassium Chloride | Potassium Chloride | 155 | 62 |
| Benazepril Hcl | Benazepril Hcl | 141 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 58 |
| Alprazolam | Alprazolam | 136 | 31 |
| Azelastine Hcl | Azelastine Hcl | 127 | 59 |
| Ibuprofen | Ibuprofen | 123 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 17 |
| Alendronate Sodium | Alendronate Sodium | 117 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 41 |
| Finasteride | Finasteride | 111 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 33 |
| Atenolol | Atenolol | 109 | 32 |
| Allopurinol | Allopurinol | 107 | 31 |
| Sertraline Hcl | Sertraline Hcl | 107 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 50 |
| Meloxicam | Meloxicam | 104 | 37 |
| Buspirone Hcl | Buspirone Hcl | 99 | 31 |
| Ezetimibe | Ezetimibe | 94 | 29 |
| Pregabalin | Pregabalin | 92 | 19 |
| Montelukast Sodium | Montelukast Sodium | 90 | 26 |
| Ozempic | Semaglutide | 87 | 23 |
| Synthroid | Levothyroxine Sodium | 86 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 31 |
| Methylprednisolone | Methylprednisolone | 85 | 74 |
| Bupropion Xl | Bupropion Hcl | 84 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 32 |
| Sildenafil Citrate | Sildenafil Citrate | 78 | 21 |
| Lovastatin | Lovastatin | 73 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 24 |
| Baclofen | Baclofen | 71 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 51 |
| Temazepam | Temazepam | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 61 | 21 |
| Jardiance | Empagliflozin | 60 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 17 |
| Nifedipine Er | Nifedipine | 54 | 16 |
| Lorazepam | Lorazepam | 53 | 16 |
| Cephalexin | Cephalexin | 52 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 13 |
| Spironolactone | Spironolactone | 52 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | 14 |
| Xarelto | Rivaroxaban | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 18 |
| Estradiol | Estradiol | 48 | 13 |
| Glimepiride | Glimepiride | 48 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | 13 |
| Azithromycin | Azithromycin | 45 | 43 |
| Propranolol Hcl | Propranolol Hcl | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 44 | 15 |
| Enalapril Maleate | Enalapril Maleate | 44 | 11 |
| Chlorthalidone | Chlorthalidone | 40 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 30 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 40 | 16 |
| Meclizine Hcl | Meclizine Hcl | 39 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 16 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 20 |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Valsartan | Valsartan | 29 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Calcitriol | Calcitriol | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Colchicine | Colchicine | 26 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 13 |
| Hydrocortisone | Hydrocortisone | 24 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Naproxen | Naproxen | 19 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $414.33 · 21 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, Kerendia, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error